Artboard 1

Post-FMT Follow-Up

OpenBiome works with our clinical partners to continuously monitor FMT treatment outcomes and respond to adverse events.

Meeting Reporting Requirements

A scientist wearing lab attire and looking forward

The U.S. Food and Drug Administration (FDA) considers stool for FMT an investigational drug, a classification that carries certain reporting requirements. We aggregate and share your submissions to our material tracking program with the FDA. Adherence to OpenBiome’s follow-up reporting protocol is required for continued access to FMT.

Follow-Up Reporting Instructions

Below, we have shared a follow-up reporting checklist for FMT preparations manufactured by the University of Minnesota (UMN) and OpenBiome as well as instructions for reporting an Adverse Event.

Reporting Checklist for FMT Manufactured by the University of Minnesota (UMN)

Checklist

Reporting Checklist for FMT Manufactured by OpenBiome

A scientist in lab attire holding a stool sample bag

Reporting an Adverse Event

If you suspect that one of your patients has experienced an adverse event that could be related to an FMT treatment distributed by OpenBiome, please fill out and submit OpenBiome's online Adverse Event Reporting Form within 24 hours to alert our Clinical Safety Team.

Please review the checklist on the fourth page of our Adverse Event Reporting Guide to ensure that you have the necessary information ready to complete your report. Once submitted, an OpenBiome medical professional will contact you to discuss the specifics of your case and advise whether additional reporting requirements to the FDA may be needed.

Contact Us

If you have any questions regarding an adverse event, please contact us at safety@openbiome.org or call (617) 575-2201, option 9.

ThankYou

Thank You

Thank you for enabling OpenBiome’s mission of serving patients in need, as well as proactively monitoring the efficacy of FMT treatments manufactured by the University of Minnesota on a network-wide and per-donor basis.
The safety and efficacy data you provide will be used to optimize treatment for patients and inform the design of future microbiome-based therapies.

Help us build a world where the full potential of the microbiome radically improves health for all

Scroll To Top